AI Engines For more Details: Perplexity Kagi Labs You
Cerebral Vasodilation: Vincamine is believed to improve cerebral blood flow by acting as a vasodilator, dilating blood vessels in the brain. This increased blood flow may enhance oxygen and nutrient delivery to brain cells, supporting cognitive function and overall brain health.
Neuroprotective Effects: Vincamine has been studied for its potential neuroprotective properties, particularly in conditions associated with reduced cerebral blood flow or ischemia. It may help protect neurons from damage caused by ischemic injury, hypoxia, or oxidative stress, thereby preserving cognitive function and reducing the risk of neurodegenerative diseases.
Cognitive Enhancement: Some research suggests that vincamine may have cognitive-enhancing effects, including improvements in memory, attention, and executive function. These effects are thought to be mediated by its ability to increase cerebral blood flow, enhance glucose utilization in the brain, and modulate neurotransmitter activity.
Antioxidant Activity: Vincamine exhibits antioxidant properties, which may help reduce oxidative stress and inflammation in the brain. By scavenging free radicals and inhibiting oxidative damage to cellular components, vincamine may contribute to neuroprotection and cognitive health.
Anti-inflammatory Effects: Vincamine has been reported to possess anti-inflammatory properties, which could be beneficial in mitigating neuroinflammation and associated neurodegenerative processes. By suppressing inflammatory signaling pathways and cytokine production, vincamine may help protect against neuronal injury and cognitive decline.
Clinical Applications: Vincamine is used clinically in some countries for the treatment of cerebrovascular disorders, cognitive impairment, and age-related cognitive decline. It may also be prescribed as an adjunctive therapy in the management of conditions such as stroke, vascular dementia, and Alzheimer's disease.
Safety and Tolerability: Vincamine is generally well-tolerated when used at recommended doses. Common side effects may include gastrointestinal disturbances, headache, dizziness, and flushing. Rare adverse effects such as hypotension, arrhythmias, and allergic reactions have been reported with high doses or prolonged use.
Drug Interactions: Vincamine may interact with certain medications, particularly those affecting blood clotting or platelet function. Caution is advised when combining vincamine with anticoagulants, antiplatelet agents, or drugs that affect hemostasis to avoid the risk of bleeding or hemorrhage.
Regulatory Status: The regulatory status of vincamine varies by country. In some regions, it is available as a prescription drug, while in others, it may be classified as a dietary supplement or over-the-counter medication. Consultation with a healthcare professional is recommended before initiating vincamine therapy to ensure appropriate use and monitoring.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Ruminococcus | genus | Decreases | 👪 Source Study | |
| Eggerthella | genus | Decreases | 👪 Source Study | |
| Lachnospira | genus | Decreases | 👪 Source Study | |
| Eggerthella lenta | species | Decreases | 📓 Source Study | |
| Ruminococcus bromii | species | Decreases | 📓 Source Study | |
| Lachnospira eligens | species | Decreases | 📓 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | 0 |
| Allergies | 0.6 | 0.3 | 1 |
| Allergy to milk products | 0.3 | 0.3 | |
| Alzheimer's disease | 0.6 | 0.6 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0.3 | 0 |
| Ankylosing spondylitis | 0.3 | 0.6 | -1 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Asthma | 0.4 | 0.4 | |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 0.6 | 0.6 | |
| Autism | 0.7 | 0.6 | 0.17 |
| Bipolar Disorder | 0.6 | 0.6 | 0 |
| Brain Trauma | 0.3 | -0.3 | |
| Breast Cancer | 0.3 | -0.3 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.6 | -0.6 | |
| Cerebral Palsy | 0.3 | -0.3 | |
| Chronic Fatigue Syndrome | 0.7 | 0.3 | 1.33 |
| Chronic Kidney Disease | 0.3 | 0.3 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 0.6 | 0.3 | 1 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 0.7 | 0.7 | 0 |
| Crohn's Disease | 0.6 | 0.6 | 0 |
| deep vein thrombosis | 0.3 | 0.3 | 0 |
| Depression | 1 | 0.6 | 0.67 |
| Endometriosis | 0.6 | -0.6 | |
| Fibromyalgia | 0.3 | 0.3 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.3 | 1 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.3 | 0.3 | |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
| Heart Failure | 0.3 | 0.3 | 0 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 0.3 | 1 |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0 | 0 |
| Inflammatory Bowel Disease | 0.4 | 0.6 | -0.5 |
| Insomnia | 0.3 | 0.6 | -1 |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.3 | 0.6 | -1 |
| ischemic stroke | 0.3 | 0.3 | |
| Liver Cirrhosis | 0.6 | 0.3 | 1 |
| Long COVID | 0.6 | 0.7 | -0.17 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.4 | 0.4 | |
| Metabolic Syndrome | 0.6 | 0.3 | 1 |
| Mood Disorders | 1 | 0.9 | 0.11 |
| Multiple Sclerosis | 0.7 | 0.3 | 1.33 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| neuropathic pain | 0.3 | 0.3 | 0 |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.6 | 0 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | |
| Obesity | 0.6 | 0.9 | -0.5 |
| obsessive-compulsive disorder | 0.3 | 0.3 | |
| Osteoarthritis | 0.3 | -0.3 | |
| Osteoporosis | 0.6 | 0.6 | |
| Parkinson's Disease | 0.3 | 0.6 | -1 |
| Polycystic ovary syndrome | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.3 | -0.3 | |
| Psoriasis | 0.3 | 0.3 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.9 | 0.9 | |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 0.9 | 0.6 | 0.5 |
| scoliosis | 0.3 | -0.3 | |
| Sleep Apnea | 0.6 | 0.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.1 | -0.1 | |
| Systemic Lupus Erythematosus | 0.3 | 0.6 | -1 |
| Tic Disorder | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.3 | 0.6 | -1 |
| Type 2 Diabetes | 0.6 | 0.3 | 1 |
| Ulcerative colitis | 0.3 | 0.3 | 0 |
| Unhealthy Ageing | 0.3 | 0.3 | |
| Vitiligo | 0.6 | 0.6 |
